IL37 and Crohn disease: Recent advances in IL-23 inhibitors, including risankizumab, mirikizumab, and guselkumab, highlight their advantages over older treatments like TNF inhibitors for patients previously exposed to biological treatments or with refractory Crohn’s disease.